Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474192 | 0.85 | OPRM1 (0.64) | OPRM1OPRD1POLBGPR119 | |
| SCHEMBL5780666 | 0.80 | OPRD1 (0.51) | OPRM1OPRD1 | |
| SCHEMBL5778658 | 0.80 | OPRM1 (0.68) | OPRM1OPRD1 | |
| SCHEMBL5781201 | 0.79 | OPRD1 (0.64) | OPRM1OPRD1 | |
| SCHEMBL5781527 | 0.79 | OPRD1 (0.67) | OPRM1OPRD1 | |
| SCHEMBL5779804 | 0.78 | OPRM1 (0.65) | OPRM1OPRD1 | |
| SCHEMBL5779820 | 0.78 | OPRM1 (0.67) | OPRM1OPRD1 | |
| SCHEMBL5779863 | 0.78 | OPRD1 (0.58) | OPRM1OPRD1 | |
| SCHEMBL5780724 | 0.77 | OPRD1 (0.57) | OPRM1OPRD1 | |
| SCHEMBL5781599 | 0.77 | OPRD1 (0.59) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395575-B1 | 4-(PENYL-PIPERIDIN-4-YLIDENE-METHYL)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| US-6838468-B2 | 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | disclosed |
| US-20040147553-A1 | 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147553-A1 | 4-(phenyl-piperdin-4-ylidene methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | HTR1D, OPRD1, HTR2C | OPRM1 5/4885OPRD1 2/4885POLB 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.